Subunit Nanovaccine with Potent Cellular and Mucosal Immunity for COVID-19.
Lixin LiuZhijia LiuHaolin ChenHong LiuQiang GaoFeng CongGuangxia GaoYongming ChenPublished in: ACS applied bio materials (2020)
To combat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, we formulated the S1 subunit of the virus with two adjuvants, amphiphilic adjuvant monophosphoryl lipid A for Toll-like receptor 4 and CpG oligodeoxynucleotide for Toll-like receptor 9, into cationic liposomes to produce a potent, safer, and translatable nanovaccine. The nanovaccine can efficiently elicit a humoral immune response and strong IgA antibodies in mice. The sera from the vaccinated mice significantly inhibit SARS-CoV-2 from infecting Vero cells. Moreover, relative to the free S1 with a traditional Alum adjuvant, the nanovaccine can elicit strong T-cell immunity by activating both CD4 + and CD8 + cells.
Keyphrases
- sars cov
- toll like receptor
- respiratory syndrome coronavirus
- immune response
- coronavirus disease
- nuclear factor
- induced apoptosis
- inflammatory response
- cell cycle arrest
- early stage
- signaling pathway
- dna methylation
- dendritic cells
- metabolic syndrome
- high fat diet induced
- cell death
- endoplasmic reticulum stress
- drug delivery
- protein kinase
- gene expression
- cell proliferation
- anti inflammatory
- ulcerative colitis